Short-term efficacy of paclitaxel -coated balloon in the treatment of femoropopliteal artery disease
10.3760/cma.j.cn113855-20201201-00897
- VernacularTitle:紫杉醇药物球囊治疗股腘动脉硬化性闭塞症的早期临床结果分析
- Author:
Yuli WANG
1
;
Qihong NI
;
Shuofe YANG
;
Weilun WANG
;
Xiangjiang GUO
;
Lan ZHANG
;
Meng YE
Author Information
1. 上海交通大学医学院附属仁济医院血管外科 200120
- Keywords:
Arteriosclerosis;
Angioplasty;
Drug-coated balloon;
Femoropopliteal artery;
Restenosis
- From:
Chinese Journal of General Surgery
2021;36(9):672-676
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of drug-coated balloon (DCB) with paclitaxel in the treatment of femoropopliteal arteriosclerosis obliterans (ASO).Methods:From Dec 2016 to Dec 2018, clinical data of femoropopliteal artery disease patients treated with paclitaxel DCB in Renji Hospital, School of Medicine, Shanghai Jiaotong University were retrospectively analyzed.Results:A total of 83 patients (95 lower limbs) underwent DCB therapy. Including 50 chronic total occlusion (CTO) lesions (52.6%) with mean lesion length of (18.35±10.61) cm. Twenty-four lesions (25.3%) were moderately or severely calcified. Bail-out stent implantation was performed in 29.5% cases. The mean follow-up time was 17.5 months. Twelve months after intervention, the all-cause mortality rate was 6.0%, the major amputation rate was 4.3%, the primary patency rate was 60.6%, the primary assisted patency rate was 72.4%, the secondary patency rate was 83.4%, and the freedom rate from clinically-driven target lesion revascularization(F-TLR) was 77.0%. Moderate to severe calcification was an independent risk factor for the primary patency of DCB therapy.Conclusion:DCB is a safe and effective endovascular therapy for femoropopliteal artery disease.
